Stockreport

Sage (SAGE) Down 20% on Parkinson's Study Missing Primary Goal [Yahoo! Finance]

Sage Therapeutics, Inc.  (SAGE) 
Last sage therapeutics, inc. earnings: 2/27 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.sagerx.com/investor-relations
PDF its lead neuropsychiatric candidate dalzanemdor in patients with mild cognitive impairment (MCI) associated with Parkinson's disease (PD). The study failed to achieve [Read more]